Literature DB >> 18452785

Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure.

Christian Butter1, Sharad Rastogi, Hans-Heinrich Minden, Jürgen Meyhöfer, Daniel Burkhoff, Hani N Sabbah.   

Abstract

OBJECTIVES: The objective of this study was to test whether cardiac contractility modulation (CCM) electric signals induce reverse molecular remodeling in myocardium of patients with heart failure.
BACKGROUND: Heart failure is associated with up-regulation of myocardial fetal and stretch response genes and down-regulation of Ca(2+) cycling genes. Treatment with CCM signals has been associated with improved symptoms and exercise tolerance in heart failure patients. We tested the impact of CCM signals on myocardial gene expression in 11 patients.
METHODS: Endomyocardial biopsies were obtained at baseline and 3 and 6 months thereafter. The CCM signals were delivered in random order of ON for 3 months and OFF for 3 months. Messenger ribonucleic acid expression was analyzed in the core lab by investigators blinded to treatment sequence. Expression of A- and B-type natriuretic peptides and alpha-myosin heavy chain (MHC), the sarcoplasmic reticulum genes SERCA-2a, phospholamban and ryanodine receptors, and the stretch response genes p38 mitogen activated protein kinase and p21 Ras were measured using reverse transcription-polymerase chain reaction and bands quantified in densitometric units.
RESULTS: The 3-month therapy OFF phase was associated with increased expression of A- and B-type natriuretic peptides, p38 mitogen activated protein kinase, and p21 Ras and decreased expression of alpha-MHC, SERCA-2a, phospholamban, and ryanodine receptors. In contrast, the 3-month ON therapy phase resulted in decreased expression of A- and B-type natriuretic peptides, p38 mitogen activated protein kinase and p21 Ras and increased expression of alpha-MHC, SERCA-2a, phospholamban, and ryanodine receptors.
CONCLUSIONS: The CCM signal treatment reverses the cardiac maladaptive fetal gene program and normalizes expression of key sarcoplasmic reticulum Ca(2+) cycling and stretch response genes. These changes may contribute to the clinical effects of CCM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452785     DOI: 10.1016/j.jacc.2008.01.036

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  34 in total

1.  Altered in vivo left ventricular torsion and principal strains in hypothyroid rats.

Authors:  Yong Chen; Aleefia Somji; Xin Yu; Julian E Stelzer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-08-20       Impact factor: 4.733

Review 2.  [Cardiac contractility modulation. A new form of therapy for patients with heart failure and narrow QRS complex?].

Authors:  T Kleemann
Journal:  Herz       Date:  2015-11       Impact factor: 1.443

Review 3.  Cardiac contractility modulation therapy in advanced systolic heart failure.

Authors:  Alexander R Lyon; Michael A Samara; David S Feldman
Journal:  Nat Rev Cardiol       Date:  2013-08-13       Impact factor: 32.419

4.  Ca2+-independent positive molecular inotropy for failing rabbit and human cardiac muscle by alpha-myosin motor gene transfer.

Authors:  Todd J Herron; Eric Devaney; Lakshmi Mundada; Erik Arden; Sharlene Day; Guadalupe Guerrero-Serna; Immanuel Turner; Margaret Westfall; Joseph M Metzger
Journal:  FASEB J       Date:  2009-10-02       Impact factor: 5.191

5.  [Electrical therapy for heart failure. Perspectives for 2011].

Authors:  C W Israel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2011-03

Review 6.  [Current impact of cardiac implantable electronic devices].

Authors:  J Kuschyk; B Rudic; M Borggrefe; I Akin
Journal:  Herz       Date:  2017-04       Impact factor: 1.443

Review 7.  Implantable cardiovascular sensors and computers: interventional heart failure strategies.

Authors:  Sakima A Smith; William T Abraham
Journal:  Curr Cardiol Rep       Date:  2012-10       Impact factor: 2.931

8.  Cardiac contractility modulation improves left ventricular systolic function partially via miR-25 mediated SERCA2A expression in rabbit trans aortic constriction heart failure model.

Authors:  Hongyun Chen; Shuang Liu; Cuiting Zhao; Zhihong Zong; Chunyan Ma; Guoxian Qi
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

9.  Device therapy in heart failure with reduced ejection fraction-cardiac resynchronization therapy and more.

Authors:  D Duncker; C Veltmann
Journal:  Herz       Date:  2018-08       Impact factor: 1.443

Review 10.  Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure.

Authors:  Larissa Lipskaia; Elie R Chemaly; Lahouaria Hadri; Anne-Marie Lompre; Roger J Hajjar
Journal:  Expert Opin Biol Ther       Date:  2010-01       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.